Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a firm specializing in radioactive compounds for the treatment of cancer, has renewed the approval of its drug YTTRIGA (Yttrium-90 chloride) by the European Commission. Five years ago the European Medicines Agency EMA approved this drug for the first time and as a result of the current renewal process the drug has now been granted an .
YTTRIGA is used as an active component in the preparation of numerous radiopharmaceuticals for the treatment of liver, intestinal and blood cancers as well as for neuroendocrine tumours. YTTRIGA is coupled with a tumour-specific peptide or with an antibody which recognizes cancer cells and binds to them maximizing the dose of ionizing radiation to the cancerous cells and minimizing radiation exposure to healthy cells.
Pharmaceutical grade YTTRIGA is produced under cGMP in Eckert & Ziegler's clean room facility in Braunschweig, from which it is shipped worldwide to radiopharmacy facilities that use it in radiolabeling preparations.
Study unveils novel bladder cancer diagnostic model based on key mitochondrial genes